Table 4.

Predictive Performance of the three models tested on the validation cohort.

End-point	Selected Features	Accuracy(%)	Sensitivity(%)	Specificity(%)	PPV(%)	NPV(%)
Warthin’s versus Malignant Tumors	ADC P25 Volume Density AEE Margins Gd	81.5 [61.9,93.7]	90.0 [68.3,98.8]	57.1 [18.4,90.1]	85.7 [71.6,93.5]	66.7 [31.7, 89.6]
Benign* versus Warthin’s Tumors	ADC P25 Volume Density AEE MinimumHistogramGradient Gd	91.7 [73.0,99.0]	85.7 [42.1,99.6]	94.1 [71.3, 99.9]	85.7 [46.7,97.6]	94.1 [72.2, 99.9]
Benign* versus Malignant Tumors	ADC P25 T2 P10 Gd Margins	89.2 [74.6,97.0]	85.0 [62.1,96.8]	94.1 [71.3,99.9]	94.4 [71.6,99.1]	84.2 [65.1, 93.8]

*Benign tumors with exclusion of Warthin’s tumors. Abbreviations as in previous tables. In squared brackets the 95% confidence interval is reported.